Comparing short‐term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3®
Abstract Aims Centrifugal continuous flow pumps are currently the state of the art in left ventricular assist device therapy. This study was conducted to compare the results after implantation of the HVAD® and the HeartMate 3®. Methods and results We retrospectively analysed preoperative and post‐op...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-06-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.12649 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544423277232128 |
|---|---|
| author | Rene Schramm Armin Zittermann Michiel Morshuis Michael Schoenbrodt Ellen vonRoessing Vera vonDossow Andreas Koster Henrik Fox Kavous Hakim‐Meibodi Jan F. Gummert |
| author_facet | Rene Schramm Armin Zittermann Michiel Morshuis Michael Schoenbrodt Ellen vonRoessing Vera vonDossow Andreas Koster Henrik Fox Kavous Hakim‐Meibodi Jan F. Gummert |
| author_sort | Rene Schramm |
| collection | DOAJ |
| description | Abstract Aims Centrifugal continuous flow pumps are currently the state of the art in left ventricular assist device therapy. This study was conducted to compare the results after implantation of the HVAD® and the HeartMate 3®. Methods and results We retrospectively analysed preoperative and post‐operative patient data of all 106 patients, who received a HeartMate 3 (HM3) at our centre between 2014 and 2018. A total of 392 patients receiving a sintered HVAD® served as controls. Patient matching was performed for age, sex, Interagency Registry for Mechanically Assisted Circulatory Support level at the time of implant, perioperative right heart failure, and implantation strategy, that is, bridge to transplant or destination therapy, as well as preoperative renal function, that is, as indicated by serum creatinine levels. A total of 79 matched pairs could be identified. During a median follow‐up of 15.3 months (range: 0–30 months), 23 (29.1%) and 19 (24.1%) patients died in the HVAD and HM3 groups, respectively, with a hazard ratio for mortality of 0.84 [95% confidence interval (CI): 0.46–1.54; P = 0.568]. Freedom from cerebrovascular events did not differ significantly between study groups, with a hazard ratio of 0.57 (95% CI: 0.23–1.45; P = 0.241). The risk of driveline infection was significantly lower in the HM3 (n = 33) than in the HVAD (n = 55) group (hazard ratio = 0.54; 95% CI: 0.35–0.84; P = 0.006). Eight HVAD, but no HM3, patients developed a pump thrombosis during follow‐up (P = 0.148). Conclusions Performance of both currently used centrifugal left ventricular assist device systems is comparable in terms of short‐term patient survival and freedom from cerebrovascular events. In our single‐centre experience, HM3 patients less frequently develop driveline infections and no pump thrombosis, which requires further evaluation. |
| format | Article |
| id | doaj-art-a293dfed0adc4e6da72d88e9fa4f174b |
| institution | Kabale University |
| issn | 2055-5822 |
| language | English |
| publishDate | 2020-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj-art-a293dfed0adc4e6da72d88e9fa4f174b2025-02-03T10:25:46ZengWileyESC Heart Failure2055-58222020-06-017390891410.1002/ehf2.12649Comparing short‐term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3®Rene Schramm0Armin Zittermann1Michiel Morshuis2Michael Schoenbrodt3Ellen vonRoessing4Vera vonDossow5Andreas Koster6Henrik Fox7Kavous Hakim‐Meibodi8Jan F. Gummert9Clinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center North Rhine Westphalia Georgstr. 11 D‐32503 Bad Oeynhausen GermanyClinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center North Rhine Westphalia Georgstr. 11 D‐32503 Bad Oeynhausen GermanyClinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center North Rhine Westphalia Georgstr. 11 D‐32503 Bad Oeynhausen GermanyClinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center North Rhine Westphalia Georgstr. 11 D‐32503 Bad Oeynhausen GermanyClinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center North Rhine Westphalia Georgstr. 11 D‐32503 Bad Oeynhausen GermanyInstitute of Anesthesiology Heart and Diabetes Center North Rhine Westphalia Bad Oeynhausen GermanyInstitute of Anesthesiology Heart and Diabetes Center North Rhine Westphalia Bad Oeynhausen GermanyClinic for Cardiology Heart and Diabetes Center North Rhine Westphalia Bad Oeynhausen GermanyClinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center North Rhine Westphalia Georgstr. 11 D‐32503 Bad Oeynhausen GermanyClinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center North Rhine Westphalia Georgstr. 11 D‐32503 Bad Oeynhausen GermanyAbstract Aims Centrifugal continuous flow pumps are currently the state of the art in left ventricular assist device therapy. This study was conducted to compare the results after implantation of the HVAD® and the HeartMate 3®. Methods and results We retrospectively analysed preoperative and post‐operative patient data of all 106 patients, who received a HeartMate 3 (HM3) at our centre between 2014 and 2018. A total of 392 patients receiving a sintered HVAD® served as controls. Patient matching was performed for age, sex, Interagency Registry for Mechanically Assisted Circulatory Support level at the time of implant, perioperative right heart failure, and implantation strategy, that is, bridge to transplant or destination therapy, as well as preoperative renal function, that is, as indicated by serum creatinine levels. A total of 79 matched pairs could be identified. During a median follow‐up of 15.3 months (range: 0–30 months), 23 (29.1%) and 19 (24.1%) patients died in the HVAD and HM3 groups, respectively, with a hazard ratio for mortality of 0.84 [95% confidence interval (CI): 0.46–1.54; P = 0.568]. Freedom from cerebrovascular events did not differ significantly between study groups, with a hazard ratio of 0.57 (95% CI: 0.23–1.45; P = 0.241). The risk of driveline infection was significantly lower in the HM3 (n = 33) than in the HVAD (n = 55) group (hazard ratio = 0.54; 95% CI: 0.35–0.84; P = 0.006). Eight HVAD, but no HM3, patients developed a pump thrombosis during follow‐up (P = 0.148). Conclusions Performance of both currently used centrifugal left ventricular assist device systems is comparable in terms of short‐term patient survival and freedom from cerebrovascular events. In our single‐centre experience, HM3 patients less frequently develop driveline infections and no pump thrombosis, which requires further evaluation.https://doi.org/10.1002/ehf2.12649Mechanical circulatory supportLeft ventricular assist deviceCentrifugal continuous flow pump |
| spellingShingle | Rene Schramm Armin Zittermann Michiel Morshuis Michael Schoenbrodt Ellen vonRoessing Vera vonDossow Andreas Koster Henrik Fox Kavous Hakim‐Meibodi Jan F. Gummert Comparing short‐term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3® ESC Heart Failure Mechanical circulatory support Left ventricular assist device Centrifugal continuous flow pump |
| title | Comparing short‐term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3® |
| title_full | Comparing short‐term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3® |
| title_fullStr | Comparing short‐term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3® |
| title_full_unstemmed | Comparing short‐term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3® |
| title_short | Comparing short‐term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3® |
| title_sort | comparing short term outcome after implantation of the heartware r hvad r and the abbott r heartmate 3 r |
| topic | Mechanical circulatory support Left ventricular assist device Centrifugal continuous flow pump |
| url | https://doi.org/10.1002/ehf2.12649 |
| work_keys_str_mv | AT reneschramm comparingshorttermoutcomeafterimplantationoftheheartwarehvadandtheabbottheartmate3 AT arminzittermann comparingshorttermoutcomeafterimplantationoftheheartwarehvadandtheabbottheartmate3 AT michielmorshuis comparingshorttermoutcomeafterimplantationoftheheartwarehvadandtheabbottheartmate3 AT michaelschoenbrodt comparingshorttermoutcomeafterimplantationoftheheartwarehvadandtheabbottheartmate3 AT ellenvonroessing comparingshorttermoutcomeafterimplantationoftheheartwarehvadandtheabbottheartmate3 AT veravondossow comparingshorttermoutcomeafterimplantationoftheheartwarehvadandtheabbottheartmate3 AT andreaskoster comparingshorttermoutcomeafterimplantationoftheheartwarehvadandtheabbottheartmate3 AT henrikfox comparingshorttermoutcomeafterimplantationoftheheartwarehvadandtheabbottheartmate3 AT kavoushakimmeibodi comparingshorttermoutcomeafterimplantationoftheheartwarehvadandtheabbottheartmate3 AT janfgummert comparingshorttermoutcomeafterimplantationoftheheartwarehvadandtheabbottheartmate3 |